Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 7,030 matching trials from the live ClinicalTrials.gov search.
Conditions
Pharmacokinetics, Pharmacodynamics, Insulin Aspart
Interventions
I004, NovoLog
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Healthy
Interventions
Rivoceranib
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Completed Phase 2 Interventional Accepts healthy volunteers Results available

AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation

NCT00075335
Conditions
Healthy
Interventions
AMD3100 (Mozobil plerixafor)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Performance Enhancing Product Use
Interventions
Suvorexant 10 mg, Zolpidem, Placebos
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 39 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Silver Spring, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Cardiac Safety of Indacaterol

NCT01263808
Conditions
Healthy Volunteers, Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg, Placebo, Placebo/moxifloxacin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Larazotide Acetate in Healthy Volunteers

NCT00386490
Conditions
Healthy
Interventions
larazotide acetate
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Healthy Volunteers
Interventions
Deflazacort and rifampin, Deflazacort and Clarithromycin
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Infection, Human Immunodeficiency Virus
Interventions
ABC/DTG/3TC FDC tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Glendale, California
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

NCT02496221
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide 50 mg, Placebo, CCK (Kinevac)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of [14C]-LY3866288 in Healthy Participants

NCT06644378
Conditions
Healthy
Interventions
[14C]-LY3866288, LY3866288
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Healthy
Interventions
BIIB061, Placebo, 14C-BIIB061
Drug
Lead sponsor
Biogen
Industry
Eligibility
20 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Evansville, Indiana • Madison, Wisconsin
Conditions
Healthy
Interventions
Metoprolol Tartrate Tablets 100 mg, Lopressor® Tablets 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

NCT01646814
Conditions
Gastroduodenal Ulceration
Interventions
PL2200, Aspirin tablets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
50 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
10
States / cities
Jupiter, Florida • South Miami, Florida • Towson, Maryland + 7 more
Completed Phase 1 Interventional Accepts healthy volunteers

Temperature Response to a Head-Neck Cooling System

NCT00025987
Conditions
Healthy
Interventions
Head and Neck Cooling System, Thermometer Pill
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition

NCT01251887
Conditions
Weight Gain, Healthy Subjects, Obesity, Women
Interventions
Linoleic Acid, Docosahexaenoic Acid, Eicosapentaenoic Acid
Dietary Supplement
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Surufatinib DDI With a PPI and a CYP3A Inducer

NCT04510649
Conditions
Healthy
Interventions
Part A, Part B
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Conditions
Head and Neck Cancer
Interventions
biologic sample preservation procedure, medical chart review
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2050
U.S. locations
4
States / cities
Nashville, Tennessee
Conditions
Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
Interventions
CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Healthy Volunteers
Interventions
INS1033, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Healthy Volunteers
Interventions
BIIB107, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Overland Park, Kansas
Completed Phase 1 Interventional Accepts healthy volunteers

Taste Assessment of Ozanimod

NCT05001152
Conditions
Healthy Volunteers
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
25 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Woburn, Massachusetts
Conditions
Hepatic Impairment
Interventions
Balcinrenone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Hialeah, Florida • Orlando, Florida • San Antonio, Texas